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Infection with and reactivation of human cytomegalovirus (CMV), Epstein-Barr virus (EBV),
and adenovirus (ADV) are frequent and severe complications in immunocompromised
recipients after hematopoietic stem cell transplantation (HSCT) or solid organ
transplantation (SOT). These serious adverse events are associated with significant
morbidity and mortality. Donor lymphocyte infusions (DLIs) are often used to treat
both viral infections and leukemia relapses after transplantation but are associated with
potentially life-threatening graft-versus-host disease (GvHD). Adoptive immunotherapy
with virus-specific cytotoxic effector T cells (CTLs) derived from seropositive donors can
rapidly reconstitute antiviral immunity after HSCT and organ transplantation. Therefore, it
can effectively prevent the clinical manifestation of these viruses with no significant acute
toxicity or increased risk of GvHD. In conditions, where patients receiving an allogeneic
cord blood (CB) transplant or a transplant from a virus-seronegative donor and since
donor blood is generally not available for solid organ recipients, allogeneic third party T-cell
donors would offer an alternative option. Recent studies showed that during granulocyte
colony-stimulating factor (G-CSF) mobilization, the functional activity of antiviral memory
T cells is impaired for a long period. This finding suggests that even stem cell donors may
not be the best source of T cells. Under these circumstances, partially human leukocyte
antigen (HLA)-matched virus-specific CTLs from healthy seropositive individuals may be
a promising option. Therefore, frequency assessments of virus-specific memory T cells
in HLA-typed healthy donors as well as in HSCT/SOT donors using a high throughput
T-cell assay were performed over a period of 4 years at Hannover Medical School. This
chapter will address the relevance and potential of a third-party T-cell donor registry and
will discuss its clinical implication for adoptive T-cell immunotherapy.
Keywords: adoptive immunotherapy, T-cell therapy, antiviral T lymphocytes, cytomegalovirus, Epstein–Barr virus,
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INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is used to
cure many malignant, benign and genetic disorders of the
bone marrow, solid tumors, immunodeficiencies, metabolic,
and autoimmune disorders (Ljungman et al., 2010). HSCT is
generally performed after administration of sublethal doses of
chemotherapy or chemoradiotherapy to achieve myeloablation,
immunosuppression and eradication of abnormal cells. Intensive
immunosuppressive therapy for prevention of graft rejection and
graft-versus-host disease (GvHD) and for treatment of GvHD
puts the patients at risk of opportunistic infections due to an
ablated or severely compromised T-cell immune response. Such
invasive conditioning procedures lead to a lack of immunological
competence, which results mainly in a decrease in the num-
ber of CD3+ T lymphocytes in the patient’s peripheral blood.
Lymphopenia increases the patient’s risk of de novo infection or
reactivation of a latent virus. This mainly occurs during the early
post-transplantation period and usually leads to a disseminated
disease. The immune reconstitution period following HSCT
(as long as 3–6 months) is therefore accompanied by a high inci-
dence of infections with various pathogens that are normally
controlled by T-cell immunity.
ROLE OF T CELLS IN TRANSPLANTATION
In allogeneic HSCT, the presence of a defined number of donor-
derived T cells in the stem cell graft may prevent graft failures,
infections or reactions caused by different pathogens (graft-
versus-infection effect, GvI) as well as disease relapses (graft-
versus-leukemia/graft-versus-tumor effect, GvL/GvT). On the
other hand, an excessive number of T cells may increase the risk
of developing GvHD. Major complications of stem cell and organ
transplantation, such as graft rejection and GvHD, are countered
by suppressing the host immune system via chemotherapy and
radiation, immunosuppressive drugs, or conditioning regimens
such as in vivo or in vitro T-cell depletion (Gooley et al., 2010).
While immunocompromised, the patient is rendered susceptible
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to a number of viral infections mainly caused by endogenous her-
pes viruses like cytomegalovirus (CMV) and Epstein-Barr virus
(EBV) and by lytic agents such as adenovirus (ADV). Infections
by several other viruses such as polyoma virus BK (BKV) and
human herpesvirus 6 (HHV-6) as well as by invasive fungal
pathogens such as Aspergillus are also reported to cause signifi-
cant complications after stem cell and solid organ transplantation
(SOT) (Marr et al., 2002; Garcia-Vidal et al., 2008; Pappas et al.,
2010; Amir et al., 2011; Breuer et al., 2012).
VIRAL COMPLICATIONS AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION AND ORGAN TRANSPLANTATION
CMV INFECTION
Human CMV is a persistent β-herpesvirus that infects most
healthy individuals during the first years of life (Khan, 2007).
Healthy CMV-seropositive individuals have a high number of
CMV-specific CD8+ and CD4+ T lymphocytes, which are essen-
tial to control viral reactivation without clinical symptoms
(Rauser et al., 2004). Immunocompromised CMV-seropositive
patients (R+) receiving a graft from a seronegative donor (D−)
have a high risk of CMV disease (Zhou et al., 2009; Borchers
et al., 2011; Ugarte-Torres et al., 2011). Additionally, it was
reported that CMV reactivation developed in 96% of D+R+
patients but in less than 50% of D+R– patients (Lilleri et al.,
2008, 2012). Reactivation of CMV results in significant morbidity
and mortality; clinical manifestations include interstitial pneu-
monitis, gastroenteritis, fever, hepatitis, encephalitis, and retinitis
(Einsele et al., 2008; Fujita et al., 2008a,b). While ganciclovir,
valganciclovir, foscarnet, and cidofovir may help to prevent or
treat CMV infection, they are associated with late-onset disease
and serious side-effects, such as nephrotoxicity, myelosuppres-
sion, and impaired immune reconstitution, leading to an increase
in invasive fungal infections and bacterial sepsis (Broers et al.,
2000; Battiwalla et al., 2007; Fujita et al., 2008a,b; Boeckh and
Ljungman, 2009). Furthermore, these drugs are often ineffective
due to primary or secondary resistance, and patients still develop
CMV disease in spite of antiviral treatment (Einsele et al., 2000;
Mori et al., 2000; Fuji et al., 2011). Hence, cellular immunity is
important for the control of CMV infection, and CMV-specific
CD8+ and CD4+ T cells are essential for efficient immune pro-
tection after both primary activation and reactivation of latent
CMV disease (Fujita et al., 2008a,b; Feuchtinger et al., 2010; Fuji
et al., 2011).
EBV INFECTION
EBV-associated post-transplant lymphoproliferative disease
(PTLD) occurring after HSCT or SOT is a potentially life-
threatening condition (Cohen, 2000; Gottschalk et al., 2005).
The overall incidence of PTLD after allogeneic HSCT is less
than 1%, but was reported to be increased after transplantation
with human leukocyte antigen (HLA)-mismatched or T-cell-
depleted grafts (Landgren et al., 2009). Further risk factors for
the development of PTLD include the degree and duration of
immunosuppressive treatment and the use of antithymocyte
globulin (ATG) with reduced-intensity transplant conditioning
(Landgren et al., 2009; Pidala et al., 2011). PTLD developing
after hematopoietic SCT usually results from donor B cells and
appears within the first 6–12 months post-transplant, when
profound deficiencies of EBV-specific cytotoxic effector T cells
(CTLs) (EBV-CTLs) occur (Meij et al., 2003). In SOT, the
incidence varies with the type of organ (1–2% after kidney trans-
plantation and up to 20% after thoracic organ transplantation)
(Trappe et al., 2012). Eighty five percentage of pediatric PTLDs
and 60–70% of adult PTLDs in Europe are EBV-associated.
Insufficient EBV-specific T-cell responses have been linked to a
higher risk of PTLD development (Guppy et al., 2007). PTLD
in SOT recipients usually originates from recipient B cells;
however, a significant percentage (10–15%) of predominantly
early PTLD in kidney or liver graft recipients restricted to the
organ graft displays donor origin (Olagne et al., 2011). Treatment
includes reduction of immunosuppressive drugs as far as toler-
ated, immunotherapy (monoclonal antibodies like Rituximab),
and cytotoxic chemotherapy. Preemptive therapy with CD20
monoclonal antibodies (Rituximab) has been attempted and
may control EBV-associated lymphoproliferation (Kuehnle et al.,
2000; van Esser et al., 2002; Trappe et al., 2012). Treatment
is often complicated by side effects, and severe complications
are foreseeable in patients with pre-existing organ dysfunction.
Second line treatment options are scarce and have not been tested
in clinical studies. Adoptive T-cell therapy using EBV-CTLs has
been successfully employed for prophylaxis and treatment of
PTLD in high-risk patients (Haque et al., 2007; Heslop et al.,
2010; Shen et al., 2011).
ADV INFECTION
The incidence of ADV infection ranges from 3 to 20%, and
is significantly higher in pediatric patients (Feuchtinger et al.,
2005; Fowler et al., 2010). Overall ADV-associated mortality
ranges from 18 to 26%. ADV infection may involve the res-
piratory, gastrointestinal and/or urinary tract. The diagnosis of
ADV infection can be difficult due to its complexity. The most
common cause of adenoviral infection after HSCT is reacti-
vation of a latent virus persisting, for example, in intestinal
mucosa. Furthermore, there are reports indicating a more than
4-fold increased risk of ADV infection in patients with grafts
from seropositive donors (Runde et al., 2001; Walls et al., 2003;
Fowler et al., 2010). Risk factors underlying this increase are:
T cell-depleted grafts (Chakrabarti et al., 2002; Lion et al.,
2003), allogeneic graft from matched unrelated donors (MUD)
(Ebner et al., 2005), acute GvHD (Bruno et al., 2003), cytotoxic
and immunosuppressive therapy (Watcharananan et al., 2010),
and lymphocytopenia (Feuchtinger et al., 2008; Watcharananan
et al., 2010). Currently, 53 different human serotypes (ADV1
to ADV53) are classified into seven species (A to G). The most
prevalent serotypes in transplant patients are ADV 1, 2, 5,
31, and 41. In 49 pediatric patients who received a stem cell
transplant at Hannover Medical School (MHH) from 2003 to
2011, sequence analysis revealed ADV species A (1% ADV18,
20.5% ADV31), B (4% ADV3), C (20.5% ADV1, 32% ADV2,
4% ADV6), E (8% ADV4), and F (10% ADV41) (Mynarek
et al., submitted). Incidence of ADV viremia was high (50%)
with mostly asymptomatic patients, who developed only low
viral loads. Despite a low ADV-related mortality rate of 0.84%
in this cohort, high peak ADV blood loads were a significant
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and independent risk factor for survival after HSCT. Cidofovir
and Ribavirin have been used to treat immunocompromised
patients suffering from ADV infection (Lankester et al., 2004;
Lindemans et al., 2010). However, these antiviral agents were
shown to limit but not clear the infection and are associated
with severe side effects. Recent studies indicate that the elimi-
nation of ADV is only achieved by recovery of cellular immu-
nity (Feuchtinger et al., 2006). Therefore, the adoptive transfer
of antigen-specific T cells could be an effective and non-toxic
alternative strategy.
ADOPTIVE T-CELL THERAPY USING ANTIVIRAL T CELLS
Although donor lymphocyte infusions (DLIs) can be used after
transplantation to treat both viral infections and leukemia
relapses, they are associated with potentially life-threatening
GvHD (Collins et al., 2000; Choi et al., 2005). The short-
comings of conventional therapies have increased the interest
in an immunotherapeutic approach to treat viral disorders. It
was recently shown that the adoptive transfer of antiviral cyto-
toxic T lymphocytes directed against CMV (Einsele et al., 2008;
Mackinnon et al., 2008; Brestrich et al., 2009; Feuchtinger et al.,
2010; Peggs et al., 2011), EBV (Haque et al., 2010; Heslop et al.,
2010; Moosmann et al., 2010; Doubrovina et al., 2012), and ADV
(Feuchtinger et al., 2008; Hoffman, 2009; Zandvliet et al., 2010;
Qasim et al., 2011) isolated from seropositive donors can rapidly
reconstitute antiviral immunity after stem cell and organ trans-
plantation without significant toxicity and with limited increase
in GvHD. Infusions of peripheral blood-derived T-lymphocyte
lines enriched in multivirus (CMV, EBV, and ADV)-specific T
cells reproducibly controlled infections by all three viruses after
allogeneic HSCT and may form the basis of future adoptive
immunotherapy trials in patients at risk of multiple infections
(Leen et al., 2006; Fujita et al., 2008a,b; Khanna et al., 2011;
Zandvliet et al., 2011; Gerdemann et al., 2012).
Although the minimal frequency of antigen-specific T cells
required to mediate an antiviral effect in patients is not known
it is likely to vary widely depending on the target antigen and
other factors, including quantitative and even more qualitative
properties of the effector T cells as well as the host environment.
The importance of the host environment to facilitate persistence
and function of transferred T cells has recently been elucidated
(Berger et al., 2009).
ADOPTIVE T-CELL THERAPY FOR CMV INFECTION
The presence of CD8+ and CD4+ antiviral T cells was reported
to be essential in controlling viral infection and reactivation
by restoring cellular immunity. Since the first promising results
began to emerge in the early 1990s (Greenberg et al., 1991; Riddell
et al., 1991), different strategies to generate virus-specific T lym-
phocytes for clinical use have been described. In 1995, Walter
and colleagues demonstrated that CMV reactivation after HLA-
identical allogeneic HSCT can be prevented by adoptive transfer
of CMV-specific cytotoxic T cells, which were generated in vitro
from the transplant donor and transferred to the patient (Walter
et al., 1995). To be suitable for clinical applications, the cells used
for adoptive T-cell transfer must be virus-specific T cells gener-
ated by in vitro induction and expansion from a small number of
precursor cells, over a short period of culture, under highly repro-
ducible conditions, and in accordance with good manufacturing
practice (GMP). CMV-specific memory T cells are present at high
frequencies in the blood of healthy CMV-seropositive donors.
Typically, they represent 0.5% to 4% of the CD8+ T-cell pool and
0.05% to 1.6% of the CD4+ T helper (Th) cell pool (Rentenaar
et al., 2000; Cwynarski et al., 2001). Most protocols for the
generation of virus-specific T cells use peptide-loaded monocyte-
derived dendritic cells (DCs), artificial antigen-presenting cells
(aAPCs), or CMV-infected immature dendritic cells as stimu-
lator cells (Sun et al., 1999; Peggs et al., 2001; Carlsson et al.,
2003; Oelke et al., 2003; Lozza et al., 2005; Paine et al., 2007,
2010; Lilleri et al., 2008). However, these protocols are difficult
to standardize and often laborious to adapt to GMP condi-
tions. Furthermore, previous works have defined CD4+ and/or
CD8+ T-cell responses to whole viral lysates, virally infected cells,
recombinant proteins, and various HLA-restricted viral peptides.
The majority of studies have focused on the 65 kDa matrix
phosphoprotein (pp65, also known as glycoprotein 64 and UL83)
and the immediate-early protein 1 (IE1) of CMV as immun-
odominant targets of CMV-specific T-cell responses (Solache
et al., 1999; Elkington et al., 2003; Sylwester et al., 2005).
Regarding the induction of antiviral T-cell responses, pp65 has
been recognized as a source of immunodominant epitopes that
stimulate both CTLs and T helper cells. Most pp65-specific T cells
predominantly produce effector cytokines like interferon-gamma
(IFN-γ), interleukin-2 (IL-2) and tumor necrosis factor-alpha
(TNF-α). The secretion of these cytokines is used for the detection
and enrichment of antiviral T cells (Rauser et al., 2004). HLA class
I-restricted peptides derived from CMV pp65 protein (e.g., the
HLA-A*0201-restricted CMVpp65495−503 peptide) are known to
be potent inducers of CTLs (Oelke et al., 2003; Paine et al., 2007).
Because the known peptide epitopes are restricted to certain HLA
alleles, the use of HLA-restricted peptides cannot exploit the full
range of HLA diversity present in the patient. Furthermore, the
use of HLA class I immunogenic peptides mainly leads to the gen-
eration of CD8+ T cells, resulting in the generation of an immune
response restricted to cytotoxic T cells.
ADOPTIVE T-CELL THERAPY FOR EBV INFECTION
Adoptive T-cell therapy using EBV-CTLs has been successfully
employed for prophylaxis and treatment of PTLD in high-risk
patients (Haque et al., 2007; Heslop et al., 2010; Shen et al.,
2011). EBV-transformed B-lymphoblastoid cell lines (B-LCLs)
are established as antigen-presenting cells (APCs) for the gener-
ation of EBV-specific T cells. Following this approach, Tanzina
Haque and colleagues (University of Edinburgh, UK) established
and used a bank of frozen EBV-specific CTLs generated from
the peripheral blood of Scottish blood donors to treat patients
with progressive PTLD with CTLs selected on the basis of the
best HLA-matches between the CTL donor and PTLD patient
(Wilkie et al., 2004; Haque et al., 2007). In this multicenter clin-
ical phase II trial, CTLs showed high efficacy varying according
to the degree of HLA-match (at least 3/6) and did not induce
any GvHD. Haque and colleagues demonstrated that the trans-
fer of partially HLA-matched EBV-CTLs grown from healthy
donors by repetitive antigenic stimulation is safe and results in
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tumor regression in about 60% of PTLD patients unresponsive
to at least one prior treatment (Haque et al., 2007, 2010). In
a study by Doubrovina et al., 49 HSCT patients with biopsy-
proven EBV-lymphoproliferative disease (EBV-LPD) were treated
with either HLA-compatible DLIs or HLA-compatible or HLA-
disparate EBV-specific CTLs (Doubrovina et al., 2012). Acute
GvHD was observed in 17% of all DLI recipients but in no EBV-
CTL recipients. The data further supports the findings of Haque
et al. indicating that EBV-CTLs from healthy, partially HLA-
matched third-party donors provide an easily accessible source of
effector T cells for the treatment of EBV-associated PTLD (Bollard
et al., 2012; Doubrovina et al., 2012).
Nevertheless, the use of EBV-transformed cells as APCs to
generate EBV-specific T cells for clinical use has three major limi-
tations: (1) The manufacturing process for the B-LCL-based gen-
eration of sufficient numbers of EBV-CTLs for clinical use takes
approximately 3 months (half for the generation of B-LCLs and
half for T-cell expansion). Consequently, the production of EBV-
CTLs for the individual patient with PTLD required diligent iden-
tification of patients at risk. Furthermore, the process is difficult
to standardize and poses a potential biohazard due to the presence
of live viruses. (2) So far, EBV-CTLs have mostly been man-
ufactured from autologous peripheral blood mononuclear cells
by repetitive in vitro stimulation with EBV antigens presented
by APCs. In children, the lack of EBV infection prior to organ
transplantation is an additional obstacle to the generation of suf-
ficient numbers of EBV-CTLs. (3) The coverage of latency types is
incomplete. Understanding the latency types of EBV is important
for the effective design of adoptive T-cell strategies. While EBV-
transformed B-LCLs express viral antigens representing latency
type III (10 viral proteins), these cells might not be useful for gen-
erating specific T cells that effectively target late PTLDs expressing
latency type II [only three viral proteins EBV nuclear antigen-
1 (EBNA-1), late membrane proteins (LMP) LMP1 and LMP2
expressed] or latency type I tumors (e.g., Burkitt’s lymphoma)
[see review in (Bollard et al., 2012)]. The antigenic specificity of T
cells generated by this method is further limited by the set of EBV
proteins available in the B-LCLs—they contain mostly proteins
from the early replication cycle (e.g., EBNA1-3) and no lytic pro-
teins like BZLF. Unfortunately, EBNA-1, which is expressed in all
three latency types, is poorly immunogenic (Thorley-Lawson and
Allday, 2008). This was confirmed in studies analyzing the fre-
quency of EBV-specific memory T cells in response to three com-
mercially available peptide pools (EBNA-1, BZLF1, and LMP2A)
in 195 healthy EBV-seropositive blood and platelet donors. It has
been found that T-cell populations against the BZLF1-derived
peptide pool were the most frequent in seropositive donors, as
reflected by a high number of responders: 112 (57%) vs. 90
(49%) for EBNA-1 and 64 (33%) for LMP2A (Sukdolak et al.,
submitted).
ADOPTIVE T-CELL THERAPY FOR ADV INFECTION
Feuchtinger et al. clearly demonstrated that children with ADV-
associatedmortality had no ADV-specific T cells, whereas patients
who cleared ADV infection had normal frequencies of antivi-
ral T cells (Feuchtinger et al., 2006). Since an increased risk of
adenoviral infection in immunocompromised patients has been
shown to correlate with low numbers of T cells, efforts have been
made over the past years to identify immunogenic ADV-derived
epitopes. As of now, the 53 known human serotypes (ADV1 to
ADV53) are classified into seven species (A to G). The most
prevalent serotypes in transplant patients are ADV1, 2, 4, 5, 41,
and 31. Hexon, the major capsid protein, serves as the immun-
odominant target antigen across the different serotypes of ADV.
A few hexon-derived CD8+ T-cell epitopes for ADV species C
have been identified and, for the most of them their clinical rele-
vance remains unclear. This makes diagnosis and treatment very
challenging. These epitopes are highly conserved, suggesting that
ADV-specific T cells can cross-react with ADV serotypes and may
therefore provide protection against a wide range of ADV strains
(Zandvliet et al., 2010). Feuchtinger et al. tested the specific T-cell
response to both hexon protein and whole ADV in HSCT donors
and found that 10.5% of donors had a detectable T-cell response
to whole ADV but no response to hexon protein, and 17% of
donors had no detectable T-cell response to ADV (Feuchtinger
et al., 2008). Zandvliet et al. were able to detect specific CD8+ T
cells in 6/16 healthy donors after stimulation with 15-mer hexon
peptide pool, while stimulation with peptides corresponding to
known CD8+ hexon epitopes induced responses in 3/16 donors
(Zandvliet et al., 2010). These studies clearly indicate the need to
identify more immunodominant ADV epitopes.
STRATEGIES FOR ISOLATION OF ANTIGEN-SPECIFIC T CELLS
FOR ADOPTIVE T-CELL THERAPY
Direct selection of virus-specific T cells without long-term ex
vivo stimulation and manipulation is an attractive way to gener-
ate clinical-grade antiviral T cells. The two main approaches are
separation by the use of cytokine secretion assays [e.g., interferon-
gamma (IFN-γ) secretion assay (Rauser et al., 2004; Feuchtinger
et al., 2008, 2010; Mackinnon et al., 2008; Moosmann et al.,
2010; Peggs et al., 2011)] and isolation by the use of peptide-
MHC (pMHC) multimers (Cobbold et al., 2005; Yao et al., 2008;
Casalegno-Garduno et al., 2010; Schmitt et al., 2011). Direct
isolation of antigen-specific T-cells by stimulation with anti-
genic peptides, proteins, or peptide-pools followed by cytokine
capture and magnetic isolation is a rapid method of produc-
ing antiviral T-cells according to GMP guidelines (Rauser et al.,
2004). It avoids safety and regulatory issues associated with pro-
longed T-cell culture and potential viral biohazards. Cytokine
secretion assays using recombinant proteins or synthetic pep-
tide pools consisting of overlapping peptides spanning an entire
immunodominant protein are not restricted by HLA variations,
and they enable the generation of CD4+ and/or CD8+ T-cell
responses to multiple epitopes (Rauser et al., 2004). In the case of
CMV 2, EBV 3, and ADV 1, GMP-grade peptide pools covering
the viral proteins pp65 and IE-1 (CMV); LMP-2A, EBNA-1, and
BZLF-1 (EBV); and the hexon (ADV) are now available for the
generation of clinical-grade antiviral CD4+ and CD8+ T cells,
irrespective of the HLA-type. It is known that specific CD4+
T-cell help is required to elicit and promote an efficient CD8+-
restricted CTL response to viral antigens. CD4+ T cells secrete
various cytokines to regulate and coordinate the function of T
cells and other immune cells. They are also known to be the
most effective cell population in clearing infections, such as ADV
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(Feuchtinger et al., 2006). Unfortunately, compared to the isola-
tion of T cells by pMHCmultimer technologies the purity is lower
and alloreactivity of T cells might result in undesirable immune
responses especially in HLA-mismatched or haploidentical set-
tings. Nevertheless, clinical trials showed no increase in GvHD
or graft rejection after adoptive immunotherapy using IFN-γ-
isolated antiviral T cells (Feuchtinger et al., 2006; Peggs et al.,
2011; Doubrovina et al., 2012).
The pMHC multimer technology requires knowledge of
immunodominant HLA-restricted peptide epitopes and enables
the isolation of either antigen-specific CD8+ T cells (pMHC class
I multimers) or CD4+ T cells (pMHC class II multimers) of
high purity. It is still difficult to generate the respective multimers
needed for CD4+ T-cell isolation. Cobbold and colleagues, the
first investigators to use tetramer-purified CMV-specific CD8+
T cells for adoptive transfer, were able to detect functionally
active antiviral T cells within 10 days (Cobbold et al., 2005).
In a study by Uhlin et al., tetramers corresponding to two EBV
antigens were used to treat a patient suffering from PTLD after
cord blood (CB) transplantation (Uhlin et al., 2010). Reversible
pMHC multimers (streptamers, histamers), the latest generation
of pMHCmultimer technologies, were developed in order to iso-
late antigen-specific T cells without altering their functional status
(Knabel et al., 2002; Tischer et al., 2012) and are already used clin-
ical applications (Schmitt et al., 2011). Although the results are
promising, this technology is limited to those donors who express
an HLA allele with known viral epitopes and have sufficient
numbers of memory T cells present in the peripheral blood.
T cells for adoptive immunotherapy could potentially be iso-
lated from a T lymphocyte pool phenotypically identified as
CD45RA+ CD62L+ naïve (N), CD45RO+ CD62L+ central
memory (TCM), and CD62L- effector memory (TEM) T-cells
subsets. These cells differ in phenotype, function, and homing
(Sallusto et al., 2004). Recently it was shown, that although TEM
have proliferative potential in vitro, these cells fail to survive in
primates in vivo (Berger et al., 2008). These results most likely
have implications for the types of T cells that should be selected
for adoptive transfer.
DO WE NEED THIRD-PARTY T-CELL DONORS?
The first clinical trials showed that T cells generated by the
above-described procedures can be successfully used to treat viral
infection, reactivation, or virus-induced malignancies after stem
cell and SOT. It was also shown that adoptive immunotherapy
with donor-derived virus-specific CTLs generated in vitro can
effectively prevent the clinical manifestation of these viruses with
no acute toxicity or increased risk of GvHD. In allogeneic stem cell
transplantation, seropositive stem cell donors can usually serve
as T cell donors and are available for T-cell donation. However,
some seropositive donors may not consent, may be unavailable
to provide T cells, or may not have enough antiviral memory
T cells in their blood despite seropositivity. Recent studies have
also shown that granulocyte colony-stimulating factor (G-CSF)
mobilization has a long-term negative effect on the functional
activity of T cells (Franzke et al., 2003; Toh et al., 2009). Bunse
et al. (in preparation), suggesting that antiviral memory T cells
from stem cell donors might not be the best source. Furthermore,
delayed hematologic engraftment and immune reconstitution are
a major problem in patients receiving CB transplants. These
problems may be attributable to a low stem cell dose, small
numbers of transferred T cells, the absence of memory T cells
within the CB grafts, or the hyporesponsiveness of CB APCs.
Therefore, these patients are at high risk of developing viral com-
plications as are patients receiving transplants from seronegative
donors or SOT patients receiving organ grafts from deceased
donors. CMV-seropositive immunocompromised patients (R+)
with transplants from seronegative donors (D−) were shown to
have a high risk of CMV disease (Zhou et al., 2009; Ugarte-Torres
et al., 2011). It was reported that CMV reactivation occurs in 96%
of D+R+ patients but in less than 50% of D+R– patients (Lilleri
et al., 2008; Borchers et al., 2011). Therefore, adoptive transfer
of virus-specific CTL is not a viable option for high-risk patients
(R+) with seronegative donors (D−).
Under these conditions, partially HLA-matched virus-specific
T cells from healthy seropositive individuals could be a success-
ful alternative and could play a significant role in the prevention
and treatment of viral infections in transplant recipients. Studies
on the use of HLA-matched T-cells from third-party donors for
the treatment of stem cell and organ recipients are currently in
progress.
The third-party approach was first successfully tested in SOT
and HSCT patients with EBV-associated PTLD at the University
of Edinburgh (Haque et al., 2002, 2007; Wilkie et al., 2004). As
mentioned in chapter 4.2 Haque and colleagues showed that par-
tially HLA-matched EBV-specific T cells (at least 3/6) produce a
65% response rate and a 42% complete response rate in PTLD
patients after SOT, indicating that the transferred EBV-specific T
cells were highly effective and did not induce any GvHD (Haque
et al., 2007, 2010). Later studies (Barker et al., 2010; Uhlin et al.,
2010; Doubrovina et al., 2012) including CB transplant patients
confirmed these results. O’Reilly and colleagues used partially
HLA-matched EBV-specific T cells to treat EBV lymphoprolifera-
tive disease in allogeneic HSCT recipients and achieved complete
or partial remission in 68% (Barker et al., 2010; Doubrovina et al.,
2012).
The effectiveness of third-party donor-derived T cells in treat-
ing CMV and ADV is now being investigated in various clinical
trials (e.g., in Memorial Sloan-Kettering Cancer Center’s phase II
trial on the treatment of CMV). Feuchtinger et al. reported their
results obtained with T cells from two third-party, partially HLA-
matched, unrelated CMV-specific T-cell donors to treat CB trans-
planted patients (Feuchtinger et al., 2010). The cells were rapidly
isolated from the donors using an IFN-γ cytokine secretion assay
after brief stimulation of peripheral bloodmononuclear cells with
CMV pp65. In vivo expansion of CMV-specific T cells and clear-
ance of CMV infection was observed in one patient (Schottker
et al., 2008; Feuchtinger et al., 2010). Third-party virus-specific
T cells directed against ADV were also shown to be effective for
the eradication of ADV (Qasim et al., 2011). Rooney and Leen
recently investigated the use of banks of third-party T cells spe-
cific for CMV, EBV, and ADV in HSCT patients and observed a
high (>70%) response rate to all three viruses, even in case of
only one HLA allele match between the CTL line and the recipient
(Gerdemann et al., 2012).
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THE ALLOGENEIC T-CELL DONOR REGISTRY
First results using T cells from partially HLA-matched third-
party donors are promising. The data indicate that allogeneic
T-cell therapy is an attractive option for patients suffering from
viral infections after allogeneic HSCT or organ transplantation.
Therefore, we hypothesize that a registry of HLA-typed allo-
geneic T-cell donors typed for virus-specific T cells would enable
rapid availability of T cells for adoptive immunotherapy of virus-
associated diseases in transplant recipients without an adequate
T-cell donor. This registry might provide a stand-alone off-the-
shelf product.
To gain more insight into virus-specific memory T-cell pools
in healthy donors and to identify the most efficient anti-
gens for adoptive immunotherapy, we determined the frequen-
cies of virus-specific memory T cells in healthy donors. To
date, T-cell frequencies have been determined in more than
300 HLA high-resolution typed donors at Hannover Medical
School’s Institute for Transfusion Medicine by INF-γ enzyme-
linked immunospot (ELISpot) assay and flow cytometry using
pMHC multimers (Sukdolak et al., submitted). Using these well-
established methods of T-cell monitoring (Cox et al., 2006;
Hadrup and Schumacher, 2010), we assessed the frequencies of
T cells against GMP-quality peptides and peptide pools derived
from viral proteins known to be immunodominant or subdom-
inant. For example, phosphoprotein 65 (pp65) and immediate
early (IE)−1 were used for CMV (Wills et al., 1996), BZLF1,
nuclear antigen (EBNA)−1 and latent membrane protein 2A
(LMP2A) for EBV (Houssaint et al., 2001), and hexon, the major
capsid protein of ADV, for ADV (Leen et al., 2008). For opti-
mal T-cell help and cytotoxic response, the T-cell population
should consist of CD4+ and CD8+ virus-specific T cells. For
high efficiency, these cells should also target various viral epitopes.
For each virus studied, we identified at least 61% potential CTL
donors with highly significant differences in frequencies of T cells
against each of the six viral antigens tested: pp65 and IE-1 (CMV),
BZLF1, LMP2A, and EBNA1 (EBV), and hexon (ADV).
All CMV-seropositive donors were reactive to the CMV pp65
peptide pool, whereas only 79% reacted with IE-1. One hundred
and seventy three of the EBV-seropositive donors had antigen-
specific T cells that reacted with at least one of three EBV peptide
pools, showing highest frequencies for BZLF1, and 73% of the
ADV-seropositive donors reacted with the hexon peptide pool.
Interestingly we found that in short-term in vitro peptide stim-
ulation assays for ADV and EBV a donor response to a certain
peptide may not be determined on day 0. Peptide-specific T
cells were detected by multimer staining, but overall frequencies
were lower than those obtained for the corresponding peptide
pools. The results of our study demonstrate that, depending
on the antigen used, no antiviral T cells can be detected in
approximately one-third of donors despite seropositivity, and that
serological testing for CMV by the standard ELISA technique
gives false-positive results in approximately 10% of donors. It
is important to remember that GvHD remains a dreaded side
effect and there is a particularly risk of alloreactivity, especially
in partially-HLA-matched settings (Amir et al., 2010; D’Orsogna
et al., 2010; Qasim et al., 2011). Therefore, we developed a mod-
ified granzyme B ELISpot assay to detect T-cell specificity and
alloreactivity against patient cells and used it to test T-cell effec-
tor function against unloaded PBMCs, (HLA class I-negative)
K562 cells and “patient unloaded and antigen-loaded PBMCs.”
This method can also be used to identify the best HLA-matched
allogeneic antiviral CTL donor. The HLA-types of CTLs with the
highest specific killing of “patient antigen-loaded PBMCs” were
identified and considered in partially HLA-matched allogeneic
T-cell therapy.
The results were used to establish a registry of potential T-cell
donors (allogeneic T-cell donor registry, alloTCDR) with highly
virus-specific T-cell precursors. The alloTCDR database will doc-
ument the donors’ HLA-type (class I and II high resolution),
virus serology (ADV, CMV, and EBV), virus-specific T-cell fre-
quencies, best T-cell detection method, and results of functional
and alloreactivity assays. This registry of HLA-typed allogeneic
T-cell donors profiled for virus-specific T cells will ensure the
rapid availability of T cells for adoptive immunotherapy of virus-
associated diseases in transplant recipients without an adequate
T-cell donor.
SUMMARY
Antigen-specific T cells can be effectively used in the treat-
ment of viral infection or reactivation after stem cell and SOT.
So far most studies did not show significant increase in the
development of acute toxicity or increased risk of GvHD fol-
lowing T-cell transfer. Unfortunately, for patients receiving an
allogeneic CB transplant, a transplant from a virus-naïve donor or
a transplant from a cadaveric donor no T-cell donor will be avail-
able. Furthermore, it was shown that in some cases no antiviral
memory T cells are present in the donor despite seropositiv-
ity, and that G-CSF treatment has a negative effect on antiviral
cell function. Third-party partially HLA-matched virus-specific
T cells from healthy seropositive individuals may be an option,
which can be successfully employed under these circumstances. In
future, we will extend the typing and profiling of potential third-
party donors to include the T-cell frequencies of other viruses,
such as polyoma virus BK, human herpesvirus 6, and invasive
fungal pathogens such as Aspergillus. The registry of unrelated
HLA-typed allogeneic T-cell donors profiled for virus-specific
T cells will ensure the rapid availability of T cells for adoptive
immunotherapy of pathogen-associated diseases in transplant
recipients.
ACKNOWLEDGMENTS
The authors would like to thank Cinja Sukdolak, Carola Bunse,
Sylvia Borchers, Sabine Tischer, Stephan Immenschuh, Murielle
Verboom, Lilia Goudeva and Hans–Gert Heuft for their assis-
tance and for helpful discussions. This work is supported
in part by funding from the German Research Foundation
(Deutsche Forschungsgemeinschaft, DFG) for the REBIRTH
(From Regenerative Biology to Reconstructive Therapy) Cluster
of Excellence, the Integrated Research and Treatment Center
Transplantation (IFB-Tx) funded by the German Federal
Ministry of Education and Research (reference number:
01EO0802), the German Children’s Cancer Research Fund
(Deutsche Kinderkrebshilfe), and the Immunotherapy Foundation
(Stiftung Immuntherapie).
Frontiers in Immunology | Alloimmunity and Transplantation January 2013 | Volume 3 | Article 410 | 6
Eiz-Vesper et al. Adoptive T-cell immunotherapy
REFERENCES
Amir, A., Shapiro, R., Shulman, L. M.,
Mor, E., Steinberg, R., Fleishhacker,
H., et al. (2011). BK virus infec-
tion and its effect on renal function
in pediatric liver-transplant recipi-
ents: a cross-sectional, longitudinal,
prospective study. Transplantation
92, 943–946.
Amir, A. L., D’Orsogna, L. J., Roelen, D.
L., van Loenen, M. M., Hagedoorn,
R. S., de Boer, R., et al. (2010).
Allo-HLA reactivity of virus-specific
memory T cells is common. Blood
115, 3146–3157.
Barker, J. N., Doubrovina, E., Sauter,
C., Jaroscak, J. J., Perales, M. A.,
Doubrovin, M., et al. (2010).
Successful treatment of EBV-
associated posttransplantation
lymphoma after cord blood
transplantation using third-
party EBV-specific cytotoxic T
lymphocytes. Blood 116, 5045–5049.
Battiwalla, M., Paplham, P.,
Almyroudis, N. G., McCarthy,
A., Abdelhalim, A., Elefante, A.,
et al. (2007). Leflunomide failure to
control recurrent cytomegalovirus
infection in the setting of renal
failure after allogeneic stem cell
transplantation. Transpl. Infect. Dis.
9, 28–32.
Berger, C., Jensen, M. C., Lansdorp,
P. M., Gough, M., Elliott, C., and
Riddell, S. R. (2008). Adoptive
transfer of effector CD8+ T cells
derived from central memory cells
establishes persistent T cell mem-
ory in primates. J. Clin. Invest. 118,
294–305.
Berger, C., Turtle, C. J., Jensen, M. C.,
and Riddell, S. R. (2009). Adoptive
transfer of virus-specific and tumor-
specific T cell immunity.Curr. Opin.
Immunol. 21, 224–232.
Boeckh, M., and Ljungman, P. (2009).
How we treat cytomegalovirus in
hematopoietic cell transplant recip-
ients. Blood 113, 5711–5719.
Bollard, C. M., Rooney, C. M., and
Heslop, H. E. (2012). T-cell therapy
in the treatment of post-transplant
lymphoproliferative disease. Nat.
Rev. Clin. Oncol. 9, 510–519.
Borchers, S., Luther, S., Lips, U., Hahn,
N., Kontsendorn, J., Stadler, M.,
et al. (2011). Tetramer monitoring
to assess risk factors for recurrent
cytomegalovirus reactivation and
reconstitution of antiviral immu-
nity post allogeneic hematopoietic
stem cell transplantation. Transpl.
Infect. Dis. 13, 222–236.
Brestrich, G., Zwinger, S., Fischer,
A., Schmuck, M., Rohmhild, A.,
Hammer, M. H., et al. (2009).
Adoptive T-cell therapy of a lung
transplanted patient with severe
CMV disease and resistance to
antiviral therapy. Am. J. Transplant.
9, 1679–1684.
Breuer, S., Rauch, M., Matthes-Martin,
S., and Lion, T. (2012). Molecular
diagnosis and management of viral
infections in hematopoietic stem
cell transplant recipients. Mol.
Diagn. Ther. 16, 63–77.
Broers, A. E., van Der Holt, R.,
van Esser, J. W., Gratama, J. W.,
Henzen-Logmans, S., Kuenen-
Boumeester, V., et al. (2000).
Increased transplant-related
morbidity and mortality in CMV-
seropositive patients despite highly
effective prevention of CMV disease
after allogeneic T-cell-depleted
stem cell transplantation. Blood 95,
2240–2245.
Bruno, B., Gooley, T., Hackman, R. C.,
Davis, C., Corey, L., and Boeckh,
M. (2003). Adenovirus infection
in hematopoietic stem cell trans-
plantation: effect of ganciclovir and
impact on survival. Biol. Blood
Marrow Transplant. 9, 341–352.
Carlsson, B., Cheng, W. S., Totterman,
T. H., and Essand, M. (2003). Ex
vivo stimulation of cytomegalovirus
(CMV)-specific T cells using CMV
pp65-modified dendritic cells as
stimulators. Br. J. Haematol. 121,
428–438.
Casalegno-Garduno, R., Schmitt, A.,
Yao, J.,Wang, X., Xu, X., Freund, M.,
et al. (2010). Multimer technologies
for detection and adoptive transfer
of antigen-specific T cells. Cancer
Immunol. Immunother. 59, 195–202.
Chakrabarti, S., Mautner, V., Osman,
H., Collingham, K. E., Fegan, C.
D., Klapper, P. E., et al. (2002).
Adenovirus infections following
allogeneic stem cell transplantation:
incidence and outcome in relation
to graft manipulation, immuno-
suppression, and immune recovery.
Blood 100, 1619–1627.
Choi, S. J., Lee, J. H., Lee, J. H., Kim,
S., Lee, Y. S., Seol, M., et al. (2005).
Treatment of relapsed acute lym-
phoblastic leukemia after allogeneic
bone marrow transplantation with
chemotherapy followed by G-CSF-
primed donor leukocyte infusion:
a prospective study. Bone Marrow
Transplant. 36, 163–169.
Cobbold, M., Khan, N., Pourgheysari,
B., Tauro, S., McDonald, D., Osman,
H., et al. (2005). Adoptive transfer
of cytomegalovirus-specific CTL
to stem cell transplant patients
after selection by HLA-peptide
tetramers. J. Exp. Med. 202,
379–386.
Cohen, J. I. (2000). Epstein-Barr virus
infection. N. Engl. J. Med. 343,
481–492.
Collins, R. H. Jr., Goldstein, S., Giralt,
S., Levine, J., Porter, D., Drobyski,
W., et al. (2000). Donor leuko-
cyte infusions in acute lymphocytic
leukemia. Bone Marrow Transplant.
26, 511–516.
Cox, J. H., Ferrari, G., and Janetzki,
S. (2006). Measurement of cytokine
release at the single cell level using
the ELISPOT assay. Methods 38,
274–282.
Cwynarski, K., Ainsworth, J., Cobbold,
M., Wagner, S., Mahendra, P.,
Apperley, J., et al. (2001). Direct
visualization of cytomegalovirus-
specific T-cell reconstitution after
allogeneic stem cell transplantation.
Blood 97, 1232–1240.
D’Orsogna, L. J., Roelen, D. L.,
Doxiadis, I. I., and Claas, F. H.
(2010). Alloreactivity from human
viral specific memory T-cells.
Transpl. Immunol. 23, 149–155.
Doubrovina, E., Oflaz-Sozmen, B.,
Prockop, S. E., Kernan, N. A.,
Abramson, S., Teruya-Feldstein, J.,
et al. (2012). Adoptive immunother-
apy with unselected or EBV-specific
T cells for biopsy-proven EBV+
lymphomas after allogeneic
hematopoietic cell transplantation.
Blood 119, 2644–2656.
Ebner, K., Suda, M., Watzinger, F., and
Lion, T. (2005). Molecular detec-
tion and quantitative analysis of the
entire spectrum of human aden-
oviruses by a two-reaction real-time
PCR assay. J. Clin. Microbiol. 43,
3049–3053.
Einsele, H., Hebart, H., Kauffmann-
Schneider, C., Sinzger, C., Jahn,
G., Bader, P., et al. (2000). Risk
factors for treatment failures in
patients receiving PCR-based pre-
emptive therapy for CMV infec-
tion. Bone Marrow Transplant. 25,
757–763.
Einsele, H., Kapp, M., and Grigoleit, G.
U. (2008). CMV-specific T cell ther-
apy. Blood Cells Mol. Dis. 40, 71–75.
Elkington, R., Walker, S., Crough, T.,
Menzies, M., Tellam, J., Bharadwaj,
M., et al. (2003). Ex vivo pro-
filing of CD8+-T-cell responses
to human cytomegalovirus reveals
broad and multispecific reactivities
in healthy virus carriers. J. Virol. 77,
5226–5240.
Feuchtinger, T., Lucke, J., Hamprecht,
K., Richard, C., Handgretinger,
R., Schumm, M., et al. (2005).
Detection of adenovirus-specific T
cells in children with adenovirus
infection after allogeneic stem cell
transplantation. Br. J. Haematol.
128, 503–509.
Feuchtinger, T., Matthes-Martin, S.,
Richard, C., Lion, T., Fuhrer, M.,
Hamprecht, K., et al. (2006). Safe
adoptive transfer of virus-specific
T-cell immunity for the treatment of
systemic adenovirus infection after
allogeneic stem cell transplantation.
Br. J. Haematol. 134, 64–76.
Feuchtinger, T., Opherk, K., Bethge,
W. A., Topp, M. S., Schuster, F. R.,
Weissinger, E. M., et al. (2010).
Adoptive transfer of pp65-specific T
cells for the treatment of chemore-
fractory cytomegalovirus disease
or reactivation after haploidenti-
cal and matched unrelated stem
cell transplantation. Blood 116,
4360–4367.
Feuchtinger, T., Richard, C., Joachim,
S., Scheible, M. H., Schumm,
M., Hamprecht, K., et al. (2008).
Clinical grade generation of
hexon-specific T cells for adoptive
T-cell transfer as a treatment of
adenovirus infection after allo-
geneic stem cell transplantation.
J. Immunother. 31, 199–206.
Fowler, C. J., Dunlap, J., Troyer, D.,
Stenzel, P., Epner, E., and Maziarz,
R. T. (2010). Life-threatening ade-
novirus infections in the setting
of the immunocompromised allo-
geneic stem cell transplant patients.
Adv. Hematol. 2010:601548. doi:
10.1155/2010/601548
Franzke, A., Piao, W., Lauber, J.,
Gatzlaff, P., Konecke, C., Hansen,
W., et al. (2003). G-CSF as immune
regulator in T cells expressing the
G-CSF receptor: implications for
transplantation and autoimmune
diseases. Blood 102, 734–739.
Fuji, S., Kapp, M., Grigoleit, G. U.,
and Einsele, H. (2011). Adoptive
immunotherapy with virus-specific
T cells. Best Pract. Res. Clin.
Haematol. 24, 413–419.
Fujita, Y., Leen, A. M., Sun, J.,
Nakazawa, Y., Yvon, E., Heslop,
H. E., et al. (2008a). Exploiting
cytokine secretion to rapidly pro-
duce multivirus-specific T cells
for adoptive immunotherapy.
J. Immunother. 31, 665–674.
Fujita, Y., Rooney, C. M., and Heslop,
H. E. (2008b). Adoptive cellu-
lar immunotherapy for viral dis-
eases. Bone Marrow Transplant. 41,
193–198.
Garcia-Vidal, C., Upton, A., Kirby,
K. A., and Marr, K. A. (2008).
Epidemiology of invasive mold
infections in allogeneic stem cell
transplant recipients: biological risk
factors for infection according to
time after transplantation. Clin.
Infect. Dis. 47, 1041–1050.
Gerdemann, U., Katari, U., Christin, A.
S., Cruz, C. R., Tripic, T., Rousseau,
A., et al. (2012). Cytotoxic T lym-
phocytes simultaneously targeting
multiple tumor-associated antigens
www.frontiersin.org January 2013 | Volume 3 | Article 410 | 7
Eiz-Vesper et al. Adoptive T-cell immunotherapy
to treat EBV negative lymphoma.
Mol. Ther. 19, 2258–2268.
Gooley, T. A., Chien, J. W., Pergam,
S. A., Hingorani, S., Sorror, M.
L., Boeckh, M., et al. (2010).
Reduced mortality after allogeneic
hematopoietic-cell transplantation.
N. Engl. J. Med. 363, 2091–2101.
Gottschalk, S., Rooney, C. M., and
Heslop, H. E. (2005). Post-
transplant lymphoproliferative
disorders. Annu. Rev. Med. 56,
29–44.
Greenberg, P. D., Reusser, P., Goodrich,
J. M., and Riddell, S. R. (1991).
Development of a treatment reg-
imen for human cytomegalovirus
(CMV) infection in bone marrow
transplantation recipients by adop-
tive transfer of donor-derived CMV-
specific T cell clones expanded
in vitro. Ann. N.Y. Acad. Sci. 636,
184–195.
Guppy, A. E., Rawlings, E., Madrigal,
J. A., Amlot, P. L., and Barber, L.
D. (2007). A quantitative assay for
Epstein-Barr Virus-specific immu-
nity shows interferon-gamma pro-
ducing CD8+ T cells increase dur-
ing immunosuppression reduction
to treat posttransplant lymphopro-
liferative disease. Transplantation
84, 1534–1539.
Hadrup, S. R., and Schumacher, T.
N. (2010). MHC-based detec-
tion of antigen-specific CD8+ T
cell responses. Cancer Immunol.
Immunother. 59, 1425–1433.
Haque, T., McAulay, K. A., Kelly,
D., and Crawford, D. H. (2010).
Allogeneic T-cell therapy for
Epstein-Barr virus-positive post-
transplant lymphoproliferative
disease: long-term follow-up.
Transplantation 90, 93–94.
Haque, T., Wilkie, G. M., Jones, M.
M., Higgins, C. D., Urquhart, G.,
Wingate, P., et al. (2007). Allogeneic
cytotoxic T-cell therapy for EBV-
positive posttransplantation lym-
phoproliferative disease: results of
a phase 2 multicenter clinical trial.
Blood 110, 1123–1131.
Haque, T., Wilkie, G. M., Taylor, C.,
Amlot, P. L., Murad, P., Iley, A., et al.
(2002). Treatment of Epstein-Barr-
virus-positive post-transplantation
lymphoproliferative disease with
partly HLA-matched allogeneic
cytotoxic T cells. Lancet 360,
436–442.
Heslop, H. E., Slobod, K. S., Pule,
M. A., Hale, G. A., Rousseau, A.,
Smith, C. A., et al. (2010). Long-
term outcome of EBV-specific T-cell
infusions to prevent or treat EBV-
related lymphoproliferative disease
in transplant recipients. Blood 115,
925–935.
Hoffman, J. A. (2009). Adenovirus
infections in solid organ trans-
plant recipients. Curr. Opin. Organ
Transplant. 14, 625–633.
Houssaint, E., Saulquin, X., Scotet,
E., and Bonneville, M. (2001).
Immunodominant CD8 T cell
response to Epstein-Barr virus.
Biomed. Pharmacother. 55, 373–380.
Khan, N. (2007). The immunological
burden of human cytomegalovirus
infection. Arch. Immunol. Ther. Exp.
(Warsz) 55, 299–308.
Khanna, N., Stuehler, C., Conrad, B.,
Lurati, S., Krappmann, S., Einsele,
H., et al. (2011). Generation of a
multipathogen-specific T-cell prod-
uct for adoptive immunotherapy
based on activation-dependent
expression of CD154. Blood 118,
1121–1131.
Knabel, M., Franz, T. J., Schiemann,M.,
Wulf, A., Villmow, B., Schmidt, B.,
et al. (2002). Reversible MHC mul-
timer staining for functional isola-
tion of T-cell populations and effec-
tive adoptive transfer. Nat. Med. 8,
631–637.
Kuehnle, I., Huls, M. H., Liu, Z.,
Semmelmann, M., Krance, R. A.,
Brenner, M. K., et al. (2000).
CD20 monoclonal antibody (ritux-
imab) for therapy of Epstein-Barr
virus lymphoma after hemopoietic
stem-cell transplantation. Blood 95,
1502–1505.
Landgren, O., Gilbert, E. S., Rizzo,
J. D., Socie, G., Banks, P. M.,
Sobocinski, K. A., et al. (2009). Risk
factors for lymphoproliferative dis-
orders after allogeneic hematopoi-
etic cell transplantation. Blood 113,
4992–5001.
Lankester, A. C., Heemskerk, B., Claas,
E. C., Schilham, M. W., Beersma,
M. F., Bredius, R. G., et al. (2004).
Effect of ribavirin on the plasma
viral DNA load in patients with
disseminating adenovirus infection.
Clin. Infect. Dis. 38, 1521–1525.
Leen, A. M., Christin, A., Khalil, M.,
Weiss, H., Gee, A. P., Brenner, M.
K., et al. (2008). Identification
of hexon-specific CD4 and CD8
T-cell epitopes for vaccine and
immunotherapy. J. Virol. 82,
546–554.
Leen, A. M., Myers, G. D., Sili, U.,
Huls, M. H., Weiss, H., Leung,
K. S., et al. (2006). Monoculture-
derived T lymphocytes specific for
multiple viruses expand and pro-
duce clinically relevant effects in
immunocompromised individuals.
Nat. Med. 12, 1160–1166.
Lilleri, D., Fornara, C., Chiesa, A.,
Caldera, D., Alessandrino, E. P.,
and Gerna, G. (2008). Human
cytomegalovirus-specific CD4+
and CD8+ T-cell reconstitution
in adult allogeneic hematopoietic
stem cell transplant recipients and
immune control of viral infection.
Haematologica 93, 248–256.
Lilleri, D., Gerna, G., Zelini, P., Chiesa,
A., Rognoni, V., Mastronuzzi,
A., et al. (2012). Monitoring
of human cytomegalovirus and
virus-specific T-cell response in
young patients receiving allogeneic
hematopoietic stem cell transplan-
tation. PLoS ONE 7:e41648. doi:
10.1371/journal.pone.0041648
Lindemans, C. A., Leen, A. M., and
Boelens, J. J. (2010). How I treat
adenovirus in hematopoietic stem
cell transplant recipients. Blood 116,
5476–5485.
Lion, T., Baumgartinger, R., Watzinger,
F., Matthes-Martin, S., Suda, M.,
Preuner, S., et al. (2003). Molecular
monitoring of adenovirus in
peripheral blood after allogeneic
bone marrow transplantation per-
mits early diagnosis of disseminated
disease. Blood 102, 1114–1120.
Ljungman, P., Bregni, M., Brune,
M., Cornelissen, J., de Witte, T.,
Dini, G., et al. (2010). Allogeneic
and autologous transplantation
for haematological diseases, solid
tumours and immune disorders:
current practice in Europe 2009.
Bone Marrow Transplant. 45,
219–234.
Lozza, L., Lilleri, D., Percivalle,
E., Fornara, C., Comolli, G.,
Revello, M. G., et al. (2005).
Simultaneous quantification of
human cytomegalovirus (HCMV)-
specific CD4+ and CD8+ T cells by
a novel method using monocyte-
derived HCMV-infected immature
dendritic cells. Eur. J. Immunol. 35,
1795–1804.
Mackinnon, S., Thomson, K.,
Verfuerth, S., Peggs, K., and
Lowdell, M. (2008). Adoptive cel-
lular therapy for cytomegalovirus
infection following allogeneic stem
cell transplantation using virus-
specific T cells. Blood Cells Mol. Dis.
40, 63–67.
Marr, K. A., Carter, R. A., Crippa, F.,
Wald, A., and Corey, L. (2002).
Epidemiology and outcome of
mould infections in hematopoietic
stem cell transplant recipients. Clin.
Infect. Dis. 34, 909–917.
Meij, P., van Esser, J. W., Niesters, H. G.,
van Baarle, D., Miedema, F., Blake,
N., et al. (2003). Impaired recovery
of Epstein-Barr virus (EBV)-specific
CD8+ T lymphocytes after par-
tially T-depleted allogeneic stem
cell transplantation may iden-
tify patients at very high risk for
progressive EBV reactivation and
lymphoproliferative disease. Blood
101, 4290–4297.
Moosmann, A., Bigalke, I., Tischer, J.,
Schirrmann, L., Kasten, J., Tippmer,
S., et al. (2010). Effective and long-
term control of EBV PTLD after
transfer of peptide-selected T cells.
Blood 115, 2960–2970.
Mori, T., Okamoto, S., Matsuoka,
S., Yajima, T., Wakui, M.,
Watanabe, R., et al. (2000). Risk-
adapted pre-emptive therapy for
cytomegalovirus disease in patients
undergoing allogeneic bone mar-
row transplantation. Bone Marrow
Transplant. 25, 765–769.
Oelke, M., Maus, M. V., Didiano, D.,
June, C. H., Mackensen, A., and
Schneck, J. P. (2003). Ex vivo induc-
tion and expansion of antigen-
specific cytotoxic T cells by HLA-Ig-
coated artificial antigen-presenting
cells. Nat. Med. 9, 619–624.
Olagne, J., Caillard, S., Gaub, M. P.,
Chenard, M. P., and Moulin, B.
(2011). Post-transplant lymphopro-
liferative disorders: determination
of donor/recipient origin in a large
cohort of kidney recipients. Am. J.
Transplant. 11, 1260–1269.
Paine, A., Oelke, M., Blasczyk, R., and
Eiz-Vesper, B. (2007). Expansion
of human cytomegalovirus-specific
T lymphocytes from unfraction-
ated peripheral blood mononu-
clear cells with artificial antigen-
presenting cells. Transfusion 47,
2143–2152.
Paine, A., Oelke, M., Tischer, S., Heuft,
H. G., Blasczyk, R., and Eiz-Vesper,
B. (2010). Soluble recombinant
CMVpp65 spanning multiple
HLA alleles for reconstitution of
antiviral CD4+ and CD8+ T-cell
responses after allogeneic stem cell
transplantation. J. Immunother. 33,
60–72.
Pappas, P. G., Alexander, B. D., Andes,
D. R., Hadley, S., Kauffman, C.
A., Freifeld, A., et al. (2010).
Invasive fungal infections among
organ transplant recipients: results
of the Transplant-Associated
Infection Surveillance Network
(TRANSNET). Clin. Infect. Dis. 50,
1101–1111.
Peggs, K. S., Thomson, K., Samuel,
E., Dyer, G., Armoogum, J.,
Chakraverty, R., et al. (2011).
Directly selected cytomegalovirus-
reactive donor T cells confer rapid
and safe systemic reconstitution of
virus-specific immunity following
stem cell transplantation. Clin.
Infect. Dis. 52, 49–57.
Peggs, K., Verfuerth, S., and
Mackinnon, S. (2001). Induction
of cytomegalovirus (CMV)-specific
T-cell responses using dendritic
Frontiers in Immunology | Alloimmunity and Transplantation January 2013 | Volume 3 | Article 410 | 8
Eiz-Vesper et al. Adoptive T-cell immunotherapy
cells pulsed with CMV antigen: a
novel culture system free of live
CMV virions. Blood 97, 994–1000.
Pidala, J., Tomblyn, M., Nishihori,
T., Ayala, E., Field, T., Fernandez,
H., et al. (2011). ATG prevents
severe acute graft-versus-host dis-
ease in mismatched unrelated donor
hematopoietic cell transplantation.
Biol. Blood Marrow Transplant. 17,
1237–1244.
Qasim, W., Derniame, S., Gilmour,
K., Chiesa, R., Weber, M., Adams,
S., et al. (2011). Third-party virus-
specific T cells eradicate adenovi-
raemia but trigger bystander graft-
versus-host disease. Br. J. Haematol.
154, 150–153.
Rauser, G., Einsele, H., Sinzger, C.,
Wernet, D., Kuntz, G., Assenmacher,
M., et al. (2004). Rapid generation
of combined CMV-specific CD4+
and CD8+ T-cell lines for adop-
tive transfer into recipients of allo-
geneic stem cell transplants. Blood
103, 3565–3572.
Rentenaar, R. J., Gamadia, L. E., van
DerHoek, N., van Diepen, F. N.,
Boom, R., Weel, J. F., et al. (2000).
Development of virus-specific
CD4(+) T cells during primary
cytomegalovirus infection. J. Clin.
Invest. 105, 541–548.
Riddell, S. R., Reusser, P., and
Greenberg, P. D. (1991). Cytotoxic
T cells specific for cytomegalovirus:
a potential therapy for immuno-
compromised patients. Rev. Infect.
Dis. 13(Suppl. 11), S966–S973.
Runde, V., Ross, S., Trenschel, R.,
Lagemann, E., Basu, O., Renzing-
Kohler, K., et al. (2001). Adenoviral
infection after allogeneic stem cell
transplantation (SCT): report on
130 patients from a single SCT unit
involved in a prospective multi cen-
ter surveillance study. Bone Marrow
Transplant. 28, 51–57.
Sallusto, F., Geginat, J., and
Lanzavecchia, A. (2004). Central
memory and effector memory T cell
subsets: function, generation, and
maintenance. Annu. Rev. Immunol.
22, 745–763.
Schmitt, A., Tonn, T., Busch, D.
H., Grigoleit, G. U., Einsele,
H., Odendahl, M., et al. (2011).
Adoptive transfer and selec-
tive reconstitution of streptamer-
selected cytomegalovirus-specific
CD8+ T cells leads to virus clear-
ance in patients after allogeneic
peripheral blood stem cell trans-
plantation. Transfusion 51, 591–599.
Schottker, B., Feuchtinger, T., Schumm,
M., Klinker, E., Handgretinger,
R., Einsele, H., et al. (2008). Five
donors-one recipient: modeling
a mosaic of granulocytes, natural
killer and T cells from cord-blood
and third-party donors. Nat. Clin.
Pract. Oncol. 5, 291–295.
Shen, Q., Feng, W., Long, M. S., Duan,
X., Jaijakul, S., Arias, C. A., et al.
(2011). Multicentric hepatic EBV-
associated smooth muscle tumors
in an AIDS patient: a case report,
investigation of mTOR activation
and review of the literature. Int. J.
Clin. Exp. Pathol. 4, 421–429.
Solache, A., Morgan, C. L., Dodi, A.
I., Morte, C., Scott, I., Baboonian,
C., et al. (1999). Identification
of three HLA-A*0201-restricted
cytotoxic T cell epitopes in the
cytomegalovirus protein pp65
that are conserved between eight
strains of the virus. J. Immunol. 163,
5512–5518.
Sun, Q., Pollok, K. E., Burton, R. L.,
Dai, L. J., Britt, W., Emanuel, D.
J., et al. (1999). Simultaneous ex
vivo expansion of cytomegalovirus
and Epstein-Barr virus-specific
cytotoxic T lymphocytes using B-
lymphoblastoid cell lines expressing
cytomegalovirus pp65. Blood 94,
3242–3250.
Sylwester, A. W., Mitchell, B. L., Edgar,
J. B., Taormina, C., Pelte, C., Ruchti,
F., et al. (2005). Broadly targeted
human cytomegalovirus-specific
CD4+ and CD8+ T cells dominate
the memory compartments of
exposed subjects. J. Exp. Med. 202,
673–685.
Thorley-Lawson, D. A., and Allday, M.
J. (2008). The curious case of the
tumour virus: 50 years of Burkitt’s
lymphoma. Nat. Rev. Microbiol. 6,
913–924.
Tischer, S., Kaireit, T., Figueiredo,
C., Hiller, O., Maecker-Kolhoff,
B., Geyeregger, R., et al. (2012).
Establishment of the reversible
peptide-major histocompatibility
complex (pMHC) class I Histamer
technology: tool for visualiza-
tion and selection of functionally
active antigen-specific CD8+ T
lymphocytes. Int. Immunol. 24,
561–572.
Toh, H. C., Sun, L., Soe, Y., Wu, Y.,
Phoon, Y. P., Chia, W. K., et al.
(2009). G-CSF induces a potentially
tolerant gene and immunopheno-
type profile in T cells in vivo. Clin.
Immunol. 132, 83–92.
Trappe, R., Oertel, S., Leblond, V.,
Mollee, P., Sender, M., Reinke, P.,
et al. (2012). Sequential treatment
with rituximab followed by CHOP
chemotherapy in adult B-cell post-
transplant lymphoproliferative
disorder (PTLD): the prospective
international multicentre phase
2 PTLD-1 trial. Lancet Oncol.
13, 196–206.
Ugarte-Torres, A., Hoegh-Petersen, M.,
Liu, Y., Zhou, F., Williamson, T.
S., Quinlan, D., et al. (2011).
Donor serostatus has an impact
on cytomegalovirus-specific immu-
nity, cytomegaloviral disease inci-
dence, and survival in seropositive
hematopoietic cell transplant recipi-
ents. Biol. Blood Marrow Transplant.
17, 574–585.
Uhlin,M., Okas,M., Gertow, J., Uzunel,
M., Brismar, T. B., and Mattsson,
J. (2010). A novel haplo-identical
adoptive CTL therapy as a treatment
for EBV-associated lymphoma after
stem cell transplantation. Cancer
Immunol. Immunother. 59, 473–477.
van Esser, J. W., Niesters, H. G., van
der Holt, B., Meijer, E., Osterhaus,
A. D., Gratama, J. W., et al. (2002).
Prevention of Epstein-Barr virus-
lymphoproliferative disease by
molecular monitoring and pre-
emptive rituximab in high-risk
patients after allogeneic stem
cell transplantation. Blood 99,
4364–4369.
Walls, T., Shankar, A. G., and Shingadia,
D. (2003). Adenovirus: an increas-
ingly important pathogen in pae-
diatric bone marrow transplant
patients. Lancet Infect. Dis. 3, 79–86.
Walter, E. A., Greenberg, P. D., Gilbert,
M. J., Finch, R. J., Watanabe, K.
S., Thomas, E. D., et al. (1995).
Reconstitution of cellular immunity
against cytomegalovirus in recip-
ients of allogeneic bone marrow
by transfer of T-cell clones from
the donor. N. Engl. J. Med. 333,
1038–1044.
Watcharananan, S. P., Kiertiburanakul,
S., Piyatuctsanawong, W.,
Anurathapan, U., Sungkanuparph,
S., Pakakasama, S., et al. (2010).
Cytomegalovirus, adenovirus, and
polyomavirus co-infection among
pediatric recipients of allogeneic
stem cell transplantation: char-
acteristics and outcome. Pediatr.
Transplant. 14, 675–681.
Wilkie, G. M., Taylor, C., Jones,
M. M., Burns, D. M., Turner,
M., Kilpatrick, D., et al. (2004).
Establishment and characteri-
zation of a bank of cytotoxic T
lymphocytes for immunotherapy
of epstein-barr virus-associated
diseases. J. Immunother. 27,
309–316.
Wills, M. R., Carmichael, A. J., Mynard,
K., Jin, X., Weekes, M. P., Plachter,
B., et al. (1996). The human cyto-
toxic T-lymphocyte (CTL) response
to cytomegalovirus is dominated by
structural protein pp65, frequency,
specificity, and T-cell receptor usage
of pp65-specific CTL. J. Virol. 70,
7569–7579.
Yao, J., Bechter, C., Wiesneth, M.,
Harter, G., Gotz, M., Germeroth,
L., et al. (2008). Multimer staining
of cytomegalovirus phosphoprotein
65-specific T cells for diagnosis and
therapeutic purposes: a comparative
study.Clin. Infect. Dis. 46, e96–e105.
Zandvliet, M. L., Falkenburg, J. H.,
van Liempt, E., Veltrop-Duits, L.
A., Lankester, A. C., Kalpoe, J. S.,
et al. (2010). Combined CD8+ and
CD4+ adenovirus hexon-specific T
cells associated with viral clearance
after stem cell transplantation as
treatment for adenovirus infection.
Haematologica 95, 1943–1951.
Zandvliet, M. L., van Liempt, E.,
Jedema, I., Veltrop-Duits, L. A.,
Willemze, R., Guchelaar, H. J., et al.
(2011). Co-ordinated isolation
of CD8(+) and CD4(+) T cells
recognizing a broad repertoire of
cytomegalovirus pp65 and IE1
epitopes for highly specific adoptive
immunotherapy. Cytotherapy 12,
933–944.
Zhou, W., Longmate, J., Lacey, S. F.,
Palmer, J. M., Gallez-Hawkins,
G., Thao, L., et al. (2009). Impact
of donor CMV status on viral
infection and reconstitution of
multifunction CMV-specific T
cells in CMV-positive transplant
recipients. Blood 113, 6465–6476.
Conflict of Interest Statement: The
authors declare that the research
was conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 19 October 2012; accepted: 17
December 2012; published online: 28
January 2013.
Citation: Eiz-Vesper B, Maecker-Kolhoff
B and Blasczyk R (2013) Adoptive T-
cell immunotherapy from third-party
donors: characterization of donors and
set up of a T-cell donor registry. Front.
Immun. 3:410. doi: 10.3389/fimmu.
2012.00410
This article was submitted to Frontiers
in Alloimmunity and Transplantation, a
specialty of Frontiers in Immunology.
Copyright © 2013 Eiz-Vesper, Maecker-
Kolhoff and Blasczyk. This is an open-
access article distributed under the terms
of the Creative Commons Attribution
License, which permits use, distribution
and reproduction in other forums, pro-
vided the original authors and source
are credited and subject to any copy-
right notices concerning any third-party
graphics etc.
www.frontiersin.org January 2013 | Volume 3 | Article 410 | 9
